Cargando…
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
SIMPLE SUMMARY: Systemic Mastocytosis (SM) is a rare disease resulting from a clonal proliferation of mast cells. Despite the rarity of the disease, its advanced forms remain a hard core to manage in clinical practice. At this time, there are few therapeutic options available, such as midostaurin an...
Autores principales: | Mancini, Manuela, Monaldi, Cecilia, De Santis, Sara, Rondoni, Michela, Papayannidis, Cristina, Sartor, Chiara, Curti, Antonio, Bruno, Samantha, Cavo, Michele, Soverini, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833529/ https://www.ncbi.nlm.nih.gov/pubmed/35159005 http://dx.doi.org/10.3390/cancers14030738 |
Ejemplares similares
-
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022) -
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023) -
P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022) -
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019) -
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)